JTCR-016

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameJTCR-016
Drug Alias NameHigh-affinity WT1-specific TCR T cellsWT1 TCR-transduced T-cell therapyHLA-A2/WT1-specific TCR T cellsWT1-sensitised T cellsJTCR-016
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > TCR therapy
Mechanisms of ActionImmunologic cytotoxicityWilms' Tumour 1 modulators
TargetsWilms' Tumour 1
Therapy Area/IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungMesothelioma +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterJuno Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesFred Hutchinson Cancer Research CenterJuno Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesCarcinoma, Non-Small-Cell LungMesothelioma +[5] 
Inactive IndicationsLeukemia, Myeloid, AcuteHematopoietic stem cell transplantation (HSCT)

Other Information

ATC CodeN/A
Related LinksN/A